首页> 美国卫生研究院文献>Bentham Open Access >Non-Traditional Systemic Treatments for Diabetic Retinopathy: AnEvidence-Based Review
【2h】

Non-Traditional Systemic Treatments for Diabetic Retinopathy: AnEvidence-Based Review

机译:糖尿病性视网膜病变的非传统全身治疗:循证审查

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The rapid escalation in the global prevalence diabetes, with more than 30% being afflicted with diabetic retinopathy (DR), means it is likely that associated vision-threatening conditions will also rise substantially. This means that new therapeutic approaches need to be found that go beyond the current standards of diabetic care, and which are effective in the early stages of the disease. In recent decades several new pharmacological agents have been investigated for their effectiveness in preventing the appearance and progression of DR or in reversing DR; some with limited success while others appear promising. This up-to-date critical review of non-traditional systemic treatments for DR is based on the published evidence in MEDLINE spanning 1980-December 2014. It discusses a number of therapeutic options, paying particular attention to the mechanisms of action and the clinical evidence for the use of renin-angiotensin system blockade, fenofibrate and calcium dobesilate monohydrate in DR.
机译:全球普遍患糖尿病的迅速升级,其中超过30%的人患有糖尿病性视网膜病(DR),这意味着相关的威胁视力的疾病也可能会大大增加。这意味着需要找到超越当前糖尿病护理标准并且在疾病早期有效的新治疗方法。最近几十年来,已经研究了几种新的药理剂在预防DR出现和发展或逆转DR方面的有效性。一些取得的成功有限,而另一些则显示出希望。这项非传统的DR全身性治疗方法的最新评论是基于MEDLINE 1980年12月至2014年12月发表的证据。它讨论了多种治疗选择,特别关注作用机理和临床证据用于在DR中使用肾素-血管紧张素系统阻滞剂,非诺贝特和一水合苯磺酸硅钙。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号